Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti-tumor necrosis factor-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of inflammatory bowel disease. Despite their clinical benefits, anti-tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients.

Original languageEnglish
Pages (from-to)769-777
Number of pages9
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Inflammatory Bowel Diseases
Tumor Necrosis Factor-alpha
Biological Products
Vaccination
Far East
Proxy
Therapeutics
Human Influenza
Hepatitis
Autoimmune Diseases
Communicable Diseases
Neoplasms
Tuberculosis
Inflammation
Safety
Health
Infection

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{ccfbb6cbdfa14f86af83b2342f0065ee,
title = "Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease",
abstract = "Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti-tumor necrosis factor-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of inflammatory bowel disease. Despite their clinical benefits, anti-tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients.",
author = "JaeHee Cheon",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/jgh.13612",
language = "English",
volume = "32",
pages = "769--777",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

AU - Cheon, JaeHee

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti-tumor necrosis factor-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of inflammatory bowel disease. Despite their clinical benefits, anti-tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients.

AB - Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti-tumor necrosis factor-α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of inflammatory bowel disease. Despite their clinical benefits, anti-tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients.

UR - http://www.scopus.com/inward/record.url?scp=85016093965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016093965&partnerID=8YFLogxK

U2 - 10.1111/jgh.13612

DO - 10.1111/jgh.13612

M3 - Review article

VL - 32

SP - 769

EP - 777

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 4

ER -